<DOC>
	<DOCNO>NCT00431093</DOCNO>
	<brief_summary>The present trial undertaken compare effect Tibolone low-dose HRT regimen .</brief_summary>
	<brief_title>Trial Compare Effects Tibolone ( Livial® ) Continuous Combined Low-Dose Estradiol/Noresterone ( Activelle® )</brief_title>
	<detailed_description />
	<mesh_term>Tibolone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subjects must healthy postmenopausal woman , &gt; = 45 &lt; 65 year age , intact uterus . Subjects must postmenopausal less 15 year . Body Mass Index &gt; 18 = &lt; 32 kg/m2 . Voluntary write informed consent require . Any unexplained abnormal uterine bleeding menopause . Double layer endometrial thickness = 6 mm assess transvaginal ultrasonography . Treatment oral estrogen and/or progestogen therapy within 4 week prior screen , treatment transdermal therapy local estrogen application within 4 week prior screen . Any previous current unopposed estrogen administration , prior use estrogen pellet tamoxifen citrate ( occasional use estrogencontaining vaginal cream allow appropriate washout period complete ) . Estrogen combine sequential administration progestogen least 10 day per 28 day cycle . The follow washout period apply : 4 week transdermal hormonal treatment , local estrogen application nonhormonal medication know act relief vasomotor symptom ( e.g . clonidine ) 4 week phytoestrogens , tibolone , intrauterine oral progestogen oral estrogen/progestogen therapy 6 month progestogen implant injection estrogen/progestogen injectable therapy . Any subject either use phytoestrogens , tibolone , intrauterine oral progestogen , progestogen implant injection , estrogen/progestogen combination therapy nonhormonal medication know act relief vasomotor symptom observe appropriate washout period ( see previous exclusion criterion ) . Any serious disease disorder ; endocrine disorder ; ( control hypo/hyperthyroidism diabetes mellitus Type II allow ) . Diseases exogenous hormonal steroid contraindicate . History presence malignancy , except successfully treat nonmelanoma skin cancer . History presence cardiovascular cerebrovascular condition : thrombophlebitis , thrombosis thromboembolic disorder . History presence liver , gallbladder ( subject cholecystectomy exclude ) renal disease , epilepsy classical migraine headache . History presence clinically significant depression psychiatric disorder , investigator 's judgment , might compromise confound subject 's participation trial . Uncontrolled high blood pressure : systolic pressure &gt; 170 mmHg and/or diastolic pressure &gt; 105 mmHg , measure 5 minute sit position . Abnormal cervical Pap smear ( correspond PAP = III , LSIL , HSIL , ASCUS , AGCUS Bethesda classification ) Abnormal , clinically significant result mammography . Presence fibrocystic disease breast . Presence otosclerosis . Known hypersensitivity ingredient trial medication . Any subject use either steroid , drug know affect sexual functioning mood ( antidepressant , psychoactive drug , sedative , neuroleptic , narcotic , benzodiazepine ) , drug know interfere pharmacokinetics steroid ( hydantoin , primidone , rifampicin , barbiturate , carbamazepine , griseofulvin , warfarin , ketoconazole , product contain St. John 's wort ) , raloxifene hydrochloride . A washout period 4 week apply subject use drug . Sporadical use benzodiazepine ( twice less week ) allow</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>